7.68 -0.15 (-1.92%) | 03-28 09:33 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 10.24 | 1-year : | 11.66 |
Resists | First : | 8.77 | Second : | 9.98 |
Pivot price | 8.66 | |||
Supports | First : | 6.8 | Second : | 5.66 |
MAs | MA(5) : | 8.3 | MA(20) : | 8.61 |
MA(100) : | 5 | MA(250) : | 9.6 | |
MACD | MACD : | 0 | Signal : | 0.2 |
%K %D | K(14,3) : | 24.3 | D(3) : | 35.6 |
RSI | RSI(14): 44.1 | |||
52-week | High : | 20.52 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZIVO ] has closed below the lower bollinger band by 8.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ZIVO ] is to continue within current trading range. It is unclear right now based on current values. 56.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 8.01 - 8.06 | 8.06 - 8.09 |
Low: | 7.88 - 7.94 | 7.94 - 7.99 |
Close: | 7.92 - 8.01 | 8.01 - 8.08 |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Bloomfield Hills, Michigan.
Fri, 22 Mar 2024
ZIVO Bioscience (NASDAQ:ZIVO) Stock Passes Above 50 Day Moving Average of $8.12 - Defense World
Thu, 15 Feb 2024
Zivo Bioscience Inc Faces Nasdaq Delisting and Shifts to OTC Markets - TipRanks.com - TipRanks
Fri, 16 Dec 2022
Does Zivo Bioscience Inc (ZIVO) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver
Tue, 05 Oct 2021
Zivo Bioscience Inc (ZIVO) is lower by 1.53% Tuesday In Premarket Trading - InvestorsObserver
Fri, 24 Sep 2021
Top Penny Stocks Moving in Premarket Trading? Check These 4 Out - Penny Stocks
Thu, 27 May 2021
Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 3 (M) |
Held by Insiders | 2.06e+006 (%) |
Held by Institutions | 33.3 (%) |
Shares Short | 13 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -16 % |
Return on Assets (ttm) | 72.7 % |
Return on Equity (ttm) | -339 % |
Qtrly Rev. Growth | 27650 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -4.6 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -2.03 |
Dividend | 0 |
Forward Dividend | 35470 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |